相关实验视频
Updated: Feb 17, 2026
08:56
Nerve Ultrasound Protocol to Detect Dysimmune Neuropathies
Published on: October 7, 2021
3.4K
在美国,患有慢性炎症性脱髓化多神经病症的成年人实际使用治疗方法
Cécile Blein1, Chafic Karam2, Clémence Arvin-Berod1
1argenx BVBA, Ghent, Belgium.
Frontiers in neurology
|February 16, 2026
概括
类固醇和免疫球蛋白 (Ig) 是慢性炎症性脱髓化多神经病 (CIDP) 的常见治疗方法. 许多使用Ig的患者也接受类固醇,这表明治疗负担很大.
科学领域:
- 神经学 神经学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 慢性炎症脱髓性多神经病症 (CIDP) 的管理是复杂的,因为严重程度,并发症,副作用和访问问题各不相同.
- 了解美国的治疗模式对于确定CIDP护理中未满足的患者需求至关重要.
研究的目的:
- 分析在美国被诊断患有CIDP的成年患者中治疗利用率.
- 确定CIDP当前管理中的潜在缺口和未得到满足的需求.
主要方法:
- 利用科莫多健康的医疗保健地图TM数据从2016年1月到2020年12月的成年CIDP患者.
- 分析了在诊断后一年内使用CIDP治疗的描述性统计数据.
- 根据一年的使用情况,免疫球蛋白 (Ig) 用户被分为慢性 (≥8个疗程) 和间歇性 (<8个疗程).
主要成果:
- 在3,409名CIDP患者中,81%接受了治疗,19%没有接受治疗.
- 类固醇 (73%) 和Ig (65%) 是最常用的治疗方法.
- 在Ig使用者中,62%是慢性使用者,经常接受并发性类固醇治疗.
结论:
- 类固醇和Ig是美国CIDP的主要治疗方法.
- 相当数量的慢性Ig使用者也接受类固醇,这表明疾病负担更高.
- 联合频繁使用Ig和类固醇可能表明患者的负担很大,需要进一步调查.
相关概念视频
01:26Peripheral Artery Disease IV: Nursing Management
402
The nursing management of a patient with peripheral artery disease (PAD) begins with a thorough assessment of the patient’s health history and clinical manifestations.AssessmentHealth History: Evaluate the patient’s history of hypertension, hyperlipidemia, family history of cardiovascular issues, and lifestyle factors such as dietary patterns, smoking, and physical activity.Physical Examination:Assess the affected extremity for decreased or absent peripheral pulses,...
402
01:27Peripheral Artery Disease III: Interprofessional Care
374
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
374
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
561
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
561
01:21Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
462
Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
462
01:16Therapeutic Drug Monitoring: Overview and Classification
382
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
382
01:20Myasthenia Gravis: Overview and Treatment
3.1K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.1K